Patents by Inventor Arturo Reyes-Sandoval
Arturo Reyes-Sandoval has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944674Abstract: The present invention relates to particles, particularly virus-like particles (VLPs), comprising fusion polypeptides comprising selected repeat units derived from the repeating regions of Type I and Type II circumsporozoite proteins (CSP) of Plasmodium vivax (Pv), together with an amino acid sequence derived from the C-terminal PvCSP sequence. In some embodiments, the fusion polypeptide additionally comprises an amino acid sequence derived from the N-terminal PvCSP sequence and/or a surface antigen polypeptide derived from Hepatitis B virus (HBV-S). The invention also relates to nucleotide sequences coding for such fusion polypeptides, vectors and plasmids comprising such nucleotide sequences, and host cells comprising such vectors and plasmids. The invention additionally relates to compositions, particularly vaccine compositions, comprising the fusion polypeptides or VLPs for use as vaccines for the prevention of malaria.Type: GrantFiled: December 13, 2021Date of Patent: April 2, 2024Assignee: Oxford University Innovation LimitedInventor: Arturo Reyes-Sandoval
-
Publication number: 20220204916Abstract: The invention relates to parasites, and to methods for purifying a metabolically active obligate parasite of vertebrates and arthropods. The invention is especially concerned with methods of purifying Plasmodium and Theileria parasites, such as P. falciparum and T. parva, and highly motile parasite forms thereof, called sporozoites. The invention also relates to obligate parasites of vertebrates and arthropods purified by the methods of the invention and their use thereof.Type: ApplicationFiled: May 6, 2020Publication date: June 30, 2022Applicant: Imperial College Innovations LimitedInventors: Andrew Blagborough, Joshua Blight, Arturo Reyes-Sandoval, Katarzyna Sala, Jacob Baum
-
Publication number: 20220168409Abstract: The present invention relates to particles, particularly virus-like particles (VLPs), comprising fusion polypeptides comprising selected repeat units derived from the repeating regions of Type I and Type II circumsporozoite proteins (CSP) of Plasmodium vivax (Pv), together with an amino acid sequence derived from the C-terminal PvCSP sequence. In some embodiments, the fusion polypeptide additionally comprises an amino acid sequence derived from the N-terminal PvCSP sequence and/or a surface antigen polypeptide derived from Hepatitis B virus (HBV-S). The invention also relates to nucleotide sequences coding for such fusion polypeptides, vectors and plasmids comprising such nucleotide sequences, and host cells comprising such vectors and plasmids. The invention additionally relates to compositions, particularly vaccine compositions, comprising the fusion polypeptides or VLPs for use as vaccines for the prevention of malaria.Type: ApplicationFiled: December 13, 2021Publication date: June 2, 2022Inventor: Arturo REYES-SANDOVAL
-
Publication number: 20220152189Abstract: The invention relates to a nucleic acid encoding a polypeptide comprising a plurality of conserved peptide sequences, or variants thereof, wherein the conserved sequences are conserved across one or more HPV genotypes 16, 18, 31, 52, 53, and 58; and wherein the polypeptide comprises a conserved peptide sequence of each of the HPV proteins E1, E2, E4, E5, E6, and E7; and associated vaccines, viral vectors, treatment and prophylaxis.Type: ApplicationFiled: November 22, 2021Publication date: May 19, 2022Inventors: Lucy DORRELL, Joshua BLIGHT, Arturo REYES-SANDOVAL
-
Patent number: 11197920Abstract: The present invention relates to particles, particularly virus-like particles (VLPs), comprising fusion polypeptides comprising selected repeat units derived from the repeating regions of Type I and Type II circumsporozoite proteins (CSP) of Plasmodium vivax (Pv), together with an amino acid sequence derived from the C-terminal PvCSP sequence. In some embodiments, the fusion polypeptide additionally comprises an amino acid sequence derived from the N-terminal PvCSP sequence and/or a surface antigen polypeptide derived from Hepatitis B virus (HBV-S). The invention also relates to nucleotide sequences coding for such fusion polypeptides, vectors and plasmids comprising such nucleotide sequences, and host cells comprising such vectors and plasmids. The invention additionally relates to compositions, particularly vaccine compositions, comprising the fusion polypeptides or VLPs for use as vaccines for the prevention of malaria.Type: GrantFiled: May 18, 2017Date of Patent: December 14, 2021Assignee: Oxford University Innovation LimitedInventor: Arturo Reyes-Sandoval
-
Patent number: 11179456Abstract: The invention relates to a nucleic acid encoding a polypeptide comprising a plurality of conserved peptide sequences, or variants thereof, wherein the conserved sequences are conserved across one or more HPV genotypes 16, 18, 31, 52, 53, and 58; and wherein the polypeptide comprises a conserved peptide sequence of each of the HPV proteins E1, E2, E4, E5, E6, and E7; and associated vaccines, viral vectors, treatment and prophylaxis.Type: GrantFiled: August 16, 2018Date of Patent: November 23, 2021Assignee: OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Lucy Dorrell, Joshua Blight, Arturo Reyes-Sandoval
-
Publication number: 20200306358Abstract: The invention relates to a nucleic acid encoding a polypeptide comprising a plurality of conserved peptide sequences, or variants thereof, wherein the conserved sequences are conserved across one or more HPV genotypes 16, 18, 31, 52, 53, and 58; and wherein the polypeptide comprises a conserved peptide sequence of each of the HPV proteins E1, E2, E4, E5, E6, and E7; and associated vaccines, viral vectors, treatment and prophylaxis.Type: ApplicationFiled: August 16, 2018Publication date: October 1, 2020Inventors: Lucy DORRELL, Joshua BLIGHT, Arturo REYES-SANDOVAL
-
Patent number: 10350285Abstract: The invention relates to a protein comprising a plurality of conserved peptide sequences, or variants thereof, wherein at least one of the conserved sequences is conserved across all four dengue virus serotypes DENV-1, DENV-2, DENV-3 and DENV-4, and wherein the conserved sequences comprise at least part of a sequence of one or more non-structural proteins of the dengue virus serotypes. The invention further relates to associated peptides, compositions, nucleic acids, viral vectors, virus-like particles, use, prime boost vaccination kits, agents and methods.Type: GrantFiled: May 11, 2016Date of Patent: July 16, 2019Assignee: Oxford University Innovation LimitedInventors: Arturo Reyes-Sandoval, Cesar Lopez-Camacho, Joshua Blight
-
Publication number: 20190201515Abstract: The present invention relates to particles, particularly virus-like particles (VLPs), comprising fusion polypeptides comprising selected repeat units derived from the repeating regions of Type I and Type II circumsporozoite proteins (CSP) of Plasmodium vivax (Pv), together with an amino acid sequence derived from the C-terminal PvCSP sequence. In some embodiments, the fusion polypeptide additionally comprises an amino acid sequence derived from the N-terminal PvCSP sequence and/or a surface antigen polypeptide derived from Hepatitis B virus (HBV-S). The invention also relates to nucleotide sequences coding for such fusion polypeptides, vectors and plasmids comprising such nucleotide sequences, and host cells comprising such vectors and plasmids. The invention additionally relates to compositions, particularly vaccine compositions, comprising the fusion polypeptides or VLPs for use as vaccines for the prevention of malaria.Type: ApplicationFiled: May 18, 2017Publication date: July 4, 2019Inventor: Arturo REYES-SANDOVAL
-
Publication number: 20190175720Abstract: The invention relates to a Zika viral vector vaccine comprising nucleic acid encoding a Zika virus structural antigen, wherein the nucleic acid encoding a Zika virus structural antigen comprises a sequence encoding Zika virus envelope DIII, or part thereof. The invention further relates to a Zika viral vector vaccine in combination with a Chikungunya viral vector vaccine.Type: ApplicationFiled: July 28, 2017Publication date: June 13, 2019Inventors: Arturo REYES-SANDOVAL, Cesar LOPEZ-CAMA-CHO
-
Publication number: 20180193446Abstract: The invention relates to a protein comprising a plurality of conserved peptide sequences, or variants thereof, wherein at least one of the conserved sequences is conserved across all four dengue virus serotypes DENV-1, DENV-2, DENV-3 and DENV-4, and wherein the conserved sequences comprise at least part of a sequence of one or more non-structural proteins of the dengue virus serotypes. The invention further relates to associated peptides, compositions, nucleic acids, viral vectors, virus-like particles, use, prime boost vaccination kits, agents and methods.Type: ApplicationFiled: May 11, 2016Publication date: July 12, 2018Applicant: Oxford University Innovation LimitedInventors: Arturo Reyes-Sandoval, Cesar Lopez-Camacho, Joshua Blight
-
Patent number: 8734806Abstract: The invention relates to an immunogenic composition comprising an adenoviral vector and a pox viral vector, or two different adenoviral vectors, wherein one or more of the vectors encodes one or more target antigens; and related methods, uses and kits.Type: GrantFiled: December 23, 2009Date of Patent: May 27, 2014Assignee: ISIS Innovation LimitedInventors: Adrian V. S. Hill, Arturo Reyes-Sandoval
-
Publication number: 20140127258Abstract: There is provided a composition comprising: (a) a modified vaccinia virus ankara (MVA) vector, wherein said MVA vector comprises a nucleic acid sequence encoding an antigen; and (b) an adjuvant comprising a saponin, or an emulsion. There is also provided a composition comprising: (a) an adenovirus vector, wherein said adenovirus vector comprises a nucleic acid sequence encoding an antigen, and wherein the adenovirus is selected from: a group B adenovirus, a group C adenovirus, and a group E adenovirus; and (b) an adjuvant comprising a saponin, or an emulsion; wherein the group B adenovirus is not an adenovirus 35, the group C adenovirus is not Ad5 having an intact E3 gene region, and the group E adenovirus is not an adenovirus C7. Also provided are corresponding uses of the compositions in medicine.Type: ApplicationFiled: September 30, 2011Publication date: May 8, 2014Applicant: Isis Innovation LimitedInventors: Simone de Cassan, Alexander Douglas, Simon Draper, Emily Forbes, Anna Goodman, Adrian Hill, Antia Millicic, Arturo Reyes-Sandoval
-
Publication number: 20120076818Abstract: The invention relates to an immunogenic composition comprising an adenoviral vector and a pox viral vector, or two different adenoviral vectors, wherein one or more of the vectors encodes one or more target antigens; and related methods, uses and kits.Type: ApplicationFiled: December 23, 2009Publication date: March 29, 2012Applicant: ISIS INNOVATION LIMITEDInventors: Adrian V. S. Hill, Arturo Reyes-Sandoval